Macular degeneration (AMD) has emerged as one of the most expensive chronic treatments done in eye care due to the cost of some of the injectable medications used in the treatment. The early stage treatment, which involves inexpensive nutraceuticals, is simple to administer, whereas the later stage treatment involves monthly intraocular injections that are expensive and an undesirable experience for the patient. These factors lend themselves to a clinical outcome study to see if:

  • The proper use of nutraceuticals clinically slows orreduces the need for injections.
  • There is a difference in clinical results depending on when nutraceuticals are started.
  • There are certain nutraceuticals that appear to be more effective.
  • Any particular processes are most effective in driving patient compliance.
  • There are cost savings associated with best early treatments.

The Age-Related Eye Disease Study (AREDS) showed that the use of nutraceuticals slows the progression of AMD. There are many clinical variables past the guidelines provided by AREDS that you as a provider have to consider on a regular basis. The clinical study being completed by the Eye Care Registry is designed to provide additional outcomes data to assist you in making decisions that result in the best clinical outcomes for your patients.

Numerous studies have shown very poor patient compliance in the use of medications for asymptomatic conditions. Since the early phase of AMD is often asymptomatic, getting consistent patient compliance may be an important factor in obtaining the best possible outcomes. Many suppliers of nutraceuticals make claims that go past the AREDS studies as well, such as benefits of obtaining components in a particular way, or of a certain type of manufacturing process being better than other processes. There are also considerable variations in the components of different products that are all sold as viable options to treat AMD.

The scope of a comprehensive traditional study to address all of these issues is past the funding available to researchers at the current time. A clinical study that progressively addresses these issues is possible at a low cost and potentially large value. The goal you and every other provider has is for your patients get the best possible results. By tracking and analyzing the results that different providers get clinically, through the Eye Care Registry clinical study of AMD, and being able to compare the results, information that can assist you in making the best possible decisions for the treatment of your patients will emerge.

Next Study Design